The BPC-157 and TB-500 combination — known in the peptide community as the "Wolverine Stack" — is the most widely used healing peptide protocol in the world, pairing 2 compounds that address tissue repair through distinct mechanisms: BPC-157 restores localized blood supply and growth factor signaling at the injury site, while TB-500 mobilizes repair cells systemically and promotes structural tissue remodeling.
The stack is named after the Marvel character's regenerative healing ability, and it carries the enthusiasm to match — but also a significant evidence gap. A 2025 systematic review of BPC-157 identified 36 published studies, of which 35 were preclinical and 1 was clinical (a retrospective case series of 12 patients). For the combination of BPC-157 + TB-500, the published research total is zero — no preclinical studies, no clinical trials, no safety data on the pairing. Every protocol described in this article is derived from practitioner anecdote and community experience, not from controlled research.
This guide covers the synergy mechanism, what the evidence actually shows, community-standard dosing protocols, injection site logic, mixing guidance, realistic timelines, cycling recommendations, safety considerations, and how to verify quality for both compounds. For a side-by-side analysis of each compound independently, see the BPC-157 vs TB-500 comparison. For the broader context of peptide combinations, see the peptide stacking guide. For the full category overview, see the tissue repair peptides pillar page.
How Do BPC-157 and TB-500 Work Together?
BPC-157 and TB-500 address tissue repair through 2 distinct but complementary mechanisms — BPC-157 restores localized blood supply and growth factor signaling at the injury site, while TB-500 mobilizes repair cells systemically and promotes structural tissue remodeling — which is why they are combined rather than used interchangeably.
When tissue is damaged, the body's inflammatory response creates two bottlenecks that slow recovery. The first is vascular disruption — blood flow to the damaged area is compromised, limiting oxygen and nutrient delivery. The second is cell immobility — the repair cells (fibroblasts, stem cells) that rebuild tissue become trapped in place, unable to migrate to the site that needs them. BPC-157 addresses the first bottleneck. TB-500 addresses the second.
BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide derived from a protein found in human gastric juice. The majority of its published research — over 100 preclinical studies, predominantly from Prof. Predrag Sikiric's laboratory at the University of Zagreb — documents its effects on the nitric oxide (NO) system, activation of the VEGFR2 pathway (vascular endothelial growth factor receptor 2), and upregulation of growth hormone receptors on fibroblasts. In preclinical models, BPC-157 promotes angiogenesis (new blood vessel formation), stimulates collagen synthesis, and accelerates the structural repair of tendon, ligament, muscle, and gastrointestinal tissues — as reviewed in Sikiric et al.'s pleiotropic mechanisms research.
TB-500 is a synthetic fragment of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino-acid peptide first characterized by Dr. Allan Goldstein at George Washington University. TB-500 promotes tissue repair through a different biological system: regulation of actin polymerization (G-actin sequestration), which governs cell structure and enables cell migration; stimulation of VEGF-driven angiogenesis (complementing but distinct from BPC-157's VEGFR2 pathway); polarization of macrophages from pro-inflammatory M1 to anti-inflammatory M2 phenotype; and anti-fibrotic properties that reduce scar tissue formation — as documented in published Thymosin Beta-4 wound healing reviews.
The core synergy: BPC-157 reopens blood supply to damaged tissue through vasodilation and new vessel formation — but without cell mobilization, those nutrients arrive and sit unused. TB-500 mobilizes repair cells and enables them to migrate to the injury — but without adequate blood flow, those cells starve before they can rebuild anything. The Wolverine Stack exists because these 2 bottlenecks are coupled: solving one without the other produces the "half-healed" state that anyone with a nagging tendon or ligament injury knows too well.
What Does the Research Actually Show?
A 2025 systematic review of BPC-157 identified 36 published studies — 35 preclinical and 1 clinical — and the combination of BPC-157 + TB-500 has zero published studies of any kind, making the Wolverine Stack the most widely used peptide combination with no direct research to support or refute it.
The 2025 orthopaedic systematic review (published in a peer-reviewed journal, covering literature from 1993 to 2024) provides the most complete picture of the BPC-157 evidence base. The 35 preclinical studies documented that BPC-157 enhances growth hormone receptor expression, activates multiple pathways involved in cell growth and angiogenesis, and reduces inflammatory cytokines. In animal models, BPC-157 improved functional, structural, and biomechanical outcomes in muscle, tendon, ligament, and bone injuries. The single clinical study was a retrospective case series: 12 patients with chronic knee pain received a single BPC-157 intra-articular injection, and 7 of 12 reported relief lasting more than 6 months. That is the entire human clinical dataset for BPC-157 as of 2026. For the full mechanism breakdown, see the BPC-157 science deep-dive.
TB-500's parent molecule, Thymosin Beta-4, has approximately 50 preclinical studies and Phase 1 human safety data. The Phase 1 trial enrolled 84 healthy volunteers, exposed them to doses above standard community protocols for a 10-day period, and reported no serious adverse events. TB-500 (the fragment) has less independent research than the full-length Tβ4 protein. For the full mechanism breakdown, see the TB-500 science deep-dive.
The honest framing: what the preclinical data shows for each compound individually is genuinely promising — tissue repair acceleration, reduced inflammation, improved biomechanical outcomes across multiple injury types. But preclinical data does not prove human efficacy, and the combination has never been tested in any published research setting. As Dr. Eric Topol of the Scripps Research Translational Institute noted in his critical analysis "The Peptide Craze", the evidence base for use of non-GLP-1 peptides, either for off-label indications or as non-approved drugs, is wanting — and TB-500 was found to accelerate dormant tumor growth in animal experiments, a concern that warrants awareness.
What Does a Typical Wolverine Stack Protocol Look Like?
BPC-157 is dosed in micrograms (mcg) and TB-500 is dosed in milligrams (mg) — confusing these units is the most common Wolverine Stack dosing error, and it matters by a factor of 1,000.
These are community-derived protocols, not clinical guidelines. There is no FDA-approved dosing and no standardized protocol. Every number cited here comes from practitioner anecdote and community experience — not from published clinical research.
BPC-157 dosing: 250–500 mcg per day, administered as 1–2 subcutaneous injections. Most community protocols use 500 mcg/day as the standard effective dose. Some protocols split this into 250 mcg twice daily (morning and evening) for more sustained levels; others administer the full 500 mcg in a single injection. No published data supports one approach over the other.
TB-500 dosing: a 2-phase approach is most common. The loading phase (weeks 1–4) uses 2–5 mg administered twice per week — typically Monday and Thursday. The maintenance phase (weeks 5–8) reduces to 2 mg once per week. The loading/maintenance structure reflects the assumption that TB-500's systemic effects require an initial saturation period before a lower maintenance dose can sustain them.
Protocol length: 4–8 weeks is the most common range. Acute injuries (recent muscle strains, fresh tendon irritation) may resolve in 4 weeks. Chronic conditions (longstanding tendon issues, overuse syndromes, nagging joint pain) typically require the full 8 weeks. Some practitioners extend to 12 weeks for severe cases, followed by a mandatory break.
Timing: No strict spacing is required between BPC-157 and TB-500 injections when administered in the same session. Many protocols place both compounds in the morning. Some split: BPC-157 in the morning near the injury site and TB-500 in the evening systemically. Both approaches are used; neither has published evidence supporting superiority.
For dose math assistance, see Peptigrity's guide on how to calculate peptide doses. For preparation, see reconstituting peptides step by step.
Reconstitution Math for Both Compounds
BPC-157 (typical 5 mg vial): Add 2 mL bacteriostatic water. Resulting concentration: 2,500 mcg/mL. For a 250 mcg dose, draw 0.10 mL (10 units on a standard insulin syringe). For a 500 mcg dose, draw 0.20 mL (20 units).
TB-500 (typical 5 mg vial): Add 1 mL bacteriostatic water. Resulting concentration: 5 mg/mL. For a 2.5 mg dose, draw 0.50 mL (50 units). For a 2 mg dose, draw 0.40 mL (40 units).
Vials per 8-week cycle at standard doses (500 mcg/day BPC-157 + loading/maintenance TB-500): approximately 3–4 vials of BPC-157 (5 mg each) and 3–4 vials of TB-500 (5 mg each). Exact count depends on loading dose selection and reconstitution volume.
Always direct bacteriostatic water against the vial wall, not directly onto the powder. Gently swirl between palms for 30–60 seconds — never shake. Verify the solution is clear; discard if cloudy. Label each vial with the compound name, reconstitution date, and concentration. Refrigerate at 2–8°C.
Where Do You Inject BPC-157 and TB-500?
BPC-157 is most effective when injected near the injury site — subcutaneously for tendons, ligaments, and joints — while TB-500 works systemically and can be injected at any convenient subcutaneous location, which is why a typical Wolverine Stack session involves 2 injection sites or a combined syringe.
BPC-157 injection placement: Preclinical data and practitioner consensus both indicate that localized injection outperforms systemic injection for musculoskeletal targets. For a knee tendon issue, inject subcutaneously in the tissue surrounding the knee. For a shoulder injury, inject near the shoulder. For an elbow tendinopathy, inject around the affected area. The rationale is that BPC-157's primary mechanisms — NO-mediated vasodilation, VEGFR2 activation, growth factor upregulation — operate most effectively when the peptide is concentrated at the tissue that needs repair. Animal studies suggest localized delivery produces stronger effects than systemic administration for soft tissue injuries.
For gut healing goals (leaky gut, IBS, ulcers, NSAID-induced GI damage), oral BPC-157 is the preferred route — the peptide interacts directly with the gastrointestinal mucosa. This is one of the few peptides with research suggesting meaningful oral bioactivity for its primary target tissue.
TB-500 injection placement: Any convenient subcutaneous site — most commonly the abdominal fat pad. TB-500's mechanism of action (actin regulation, systemic cell migration, macrophage polarization) operates regardless of injection location. The compound distributes systemically and does not require proximity to the injury. Some practitioners also inject TB-500 near the injury site for convenience when combining with BPC-157, but this is a logistical choice, not a mechanistic one.
Subcutaneous injection technique: Clean the site with an alcohol swab. Pinch a fold of skin. Insert the needle at approximately a 45-degree angle. Inject slowly. Release the skin fold after withdrawing the needle.
Can You Mix BPC-157 and TB-500 in the Same Syringe?
BPC-157 and TB-500 can be safely drawn into the same syringe immediately before injection — both are water-soluble peptides with compatible pH profiles — but they should be reconstituted and stored in separate vials because their stability timelines differ.
For immediate injection: YES. Draw the required BPC-157 dose from its vial first, then draw the TB-500 dose from its vial into the same syringe, and inject immediately. This halves the number of injections per session without documented stability issues. Both compounds are reconstituted in bacteriostatic water and remain compatible at the pH range used for standard peptide preparations.
For storage: NO. Do not pre-mix BPC-157 and TB-500 into the same vial for multi-day use. Reconstituted BPC-157 stability is typically up to 30 days refrigerated. Reconstituted TB-500 stability is shorter — typically 1–2 weeks refrigerated. Mixing them in a single vial forces you to discard at the shorter compound's timeline, and extended co-storage increases the risk of peptide interactions, aggregation, or degradation.
Pre-blended "Wolverine" vials (typically 10 mg BPC-157 + 10 mg TB-500 in a single vial) are commercially available. They offer convenience but introduce 2 practical disadvantages. First, a fixed-ratio blend does not allow independent dose adjustment — because BPC-157 is dosed in micrograms and TB-500 in milligrams, optimal doses for each compound rarely scale at the same ratio. Second, verifying the concentration of each individual peptide in a blend requires more complex analytical methods than testing single-compound vials, which reduces verification confidence (more on this in the Quality section below).
Best practice: reconstitute each compound in its own labeled vial, store separately according to each compound's stability requirements, draw sequentially into the syringe immediately before injection, and administer promptly.
How Long Does the Wolverine Stack Take to Work?
Acute injuries such as fresh muscle strains or recent tendon irritation typically show measurable improvement in pain and mobility within 7–14 days of starting the Wolverine Stack, while chronic conditions often require 4–8 weeks before meaningful progress — and these timelines come from community reports and practitioner observation, not from controlled trials.
Acute injuries (recent strains, sprains, fresh tendon irritation): Community reports describe reduced pain and improved range of motion within the first 1–2 weeks, with significant functional progress by weeks 2–3 and potential resolution in 4–6 weeks. These are the cases that produce the most dramatic results — fresh tissue damage with active inflammatory signaling that the peptides can modulate directly.
Chronic injuries (longstanding tendon issues, overuse syndromes, nagging joint pain present for months or years): Meaningful improvement is typically not reported until weeks 4–6, with some users requiring 8–12 weeks for substantial progress. The single clinical data point — from the 2025 systematic review's case series — showed that 7 of 12 patients with chronic knee pain experienced relief lasting over 6 months after a single BPC-157 injection, but peak response took weeks to develop.
Post-surgical recovery: Anecdotal reports describe accelerated wound healing and reduced scarring when the Wolverine Stack is started shortly after procedures. No clinical timeline data exists for this application.
The "half-healed" plateau: Some users report rapid initial improvement that stalls at approximately 60–70% recovery. This can indicate the stack addressed one bottleneck (vascular repair, inflammation reduction) but a different bottleneck is now rate-limiting — mechanical loading patterns, nutritional deficits (particularly vitamin C, collagen, zinc), inadequate sleep, or the need for structured physical therapy. Peptides complement but do not replace the fundamentals of rehabilitation. Adding more peptides or increasing doses at a plateau is rarely the answer; identifying the new rate-limiting factor is.
If no improvement after 6 consistent weeks: Reassess product quality through independent testing, verify dosing accuracy (particularly the mcg vs. mg distinction), evaluate whether the injury type is appropriate for this approach, and consult a healthcare provider. Complete non-response at 6 weeks warrants investigation rather than simply extending the protocol.
Do You Need to Cycle BPC-157 and TB-500?
BPC-157 does not appear to require cycling based on available research — no receptor desensitization mechanism has been documented — but most practitioners recommend limiting continuous Wolverine Stack use to 8–12 weeks followed by a 4-week break, primarily because long-term human safety data does not exist.
BPC-157: No receptor desensitization has been documented in published research. Most protocols run BPC-157 for the duration of the healing goal (4–8 weeks) and then stop — not because of a cycling requirement, but because the purpose is injury resolution, not indefinite supplementation.
TB-500: Some practitioners recommend cycling after 8–12 weeks of continuous use, though the evidence for receptor desensitization is anecdotal. The loading/maintenance dosing structure already provides built-in dose modulation. If required dose escalation occurs (same dose producing weaker effects over time), that signals a need to begin the off-cycle — not to increase the dose.
Combined protocol: The most common approach is 8 weeks on (4-week loading + 4-week maintenance), followed by 4 weeks off if a second cycle is needed. Many users run a single cycle for a specific injury and do not repeat unless a new injury occurs. Maximum recommended continuous duration from most practitioners: 90 days (approximately 12 weeks), followed by a 30-day washout period.
Indefinite continuous use is not recommended — not because of documented harm, but because of insufficient long-term safety data. For the broader context on cycling across all peptide categories, see the peptide stacking guide.
Safety, Side Effects & Who Should NOT Use This Stack
No clinical safety data exists for the BPC-157 + TB-500 combination — but the individual compounds have favorable preclinical safety profiles, with the 2025 BPC-157 systematic review reporting no harmful effects across 35 animal studies, and Thymosin Beta-4 Phase 1 data showing no serious adverse events in 84 healthy volunteers.
Reported side effects (anecdotal — from community and practitioner reports, not clinical data): injection site warmth or redness (often interpreted as a positive sign of increased local blood flow), mild nausea, headache, temporary dizziness, and mild fatigue. These are generally reported as transient and mild.
Contraindications — who should NOT use the Wolverine Stack:
Active cancer or malignancy within the past 2 years. Both BPC-157 and TB-500 promote angiogenesis — the formation of new blood vessels. In the context of an existing tumor, new blood vessel formation could theoretically support tumor growth and metastasis. As Dr. Topol noted in "The Peptide Craze", TB-500 was found to accelerate dormant tumor growth in animal experiments. Any history of cancer should be discussed with an oncologist before considering either compound.
Pregnancy or breastfeeding. Insufficient safety data exists for either compound during pregnancy or lactation. Neither compound has been studied in pregnant or lactating populations.
Proliferative retinopathy. Angiogenesis-promoting compounds may worsen retinal pathology involving abnormal blood vessel growth.
Active autoimmune conditions. TB-500's macrophage polarization effects (M1 → M2 shift) alter immune cell behavior in ways that may be unpredictable in the context of autoimmune disease.
Both BPC-157 and TB-500 appear on the WADA Prohibited List and are classified as FDA Category 2 bulk drug substances (with potential reclassification to Category 1 pending in 2026 — see the FDA regulatory timeline). For the legal status by country, see the regulatory guide.
This stack is not a replacement for medical care, physical therapy, or surgery when indicated.
How to Verify Quality for Both Compounds
A Wolverine Stack is only as reliable as its weakest vial — and because you're running 2 compounds simultaneously, quality failure in either one makes it impossible to determine which peptide is working and which isn't.
Each compound needs its own independent, batch-specific Certificate of Analysis (COA) with 3 essential elements: HPLC purity (≥98% for research grade), mass spectrometry identity confirmation (observed molecular weight must match theoretical MW), and a testing date that corresponds to the specific batch you received.
BPC-157 has a theoretical molecular weight of approximately 1,419 Da. TB-500 molecular weight varies by the exact fragment sequence your vendor supplies — verify the specific sequence and expected MW before comparing to COA data. If the COA does not specify the molecular weight confirmed by mass spectrometry, you cannot verify identity — only purity. A product can test at 99% pure and still be the wrong compound entirely.
Pre-blended Wolverine vials are harder to verify than separate vials. Testing a blend requires more complex analytical methods to confirm the concentration of each individual peptide — a standard HPLC run on a blend will show combined peaks that are more difficult to attribute. Sourcing each compound individually with its own COA provides the highest verification confidence. If a vendor provides a single COA for a blended product, confirm that it includes separate identity confirmation for both compounds.
Red flags to watch for: a vendor provides one generic COA for both compounds in a blend (each compound should have individual verification); a COA lacks a batch number or chromatogram; purity claims are stated without supporting analytical data; the same COA appears across multiple orders placed months apart (suggesting the document is not batch-specific).
Peptigrity's independent lab test database includes HPLC purity tests for both BPC-157 and TB-500 across multiple vendors — use these to cross-reference vendor claims before purchasing. The shop reviews and trust scores provide a second verification layer based on community experience. For a complete quality verification process, see how to verify peptide quality before you buy. For documentation-specific guidance, see COA red flags and purity standards.
For compound-specific sourcing guides: where to buy BPC-157 and where to buy TB-500.
Frequently Asked Questions
Can you use oral BPC-157 with injectable TB-500?
Yes — this is a legitimate alternative protocol. Oral BPC-157 is preferred for gut-focused healing goals (leaky gut, IBS, ulcers, NSAID-induced gastrointestinal damage) because it interacts directly with the gastrointestinal mucosa. Injectable TB-500 continues to provide systemic cell migration and angiogenesis support regardless of BPC-157's administration route. Preclinical data suggests injectable BPC-157 is superior for musculoskeletal targets (tendons, ligaments, muscles), so the oral + injectable combination is most appropriate when gut healing is the primary or co-equal goal alongside systemic recovery.
Is the Wolverine Stack effective for tendons specifically?
Tendons are the tissue type with the strongest preclinical evidence for BPC-157. The 2025 systematic review documented improved functional, structural, and biomechanical outcomes in multiple tendon injury models, including Achilles tendon, rotator cuff, and quadriceps tendon. TB-500's parent molecule (Thymosin Beta-4) has also been studied in tendon and ligament repair models, with published preclinical data demonstrating enhanced cell migration and collagen deposition. However, no human tendon-specific clinical trial has been published for either compound, and the combination has never been tested in any research setting — preclinical or clinical.
Can you add CJC-1295 + Ipamorelin to the Wolverine Stack?
Yes — the 4-compound protocol (BPC-157 + TB-500 + CJC-1295 + Ipamorelin) is the most commonly asked-about multi-stack combination. The healing peptides and GH secretagogues operate through entirely separate receptor systems with no known pharmacological conflict. Typical timing: Wolverine Stack in the morning (BPC-157 near the injury, TB-500 systemically), CJC-1295 + Ipamorelin pre-sleep on an empty stomach (aligning with the natural nocturnal GH pulse). See the peptide stacking guide for full combination details.
How many vials do I need for an 8-week Wolverine Stack?
At standard doses (500 mcg/day BPC-157 + loading at 2.5 mg twice weekly for 4 weeks + maintenance at 2 mg once weekly for 4 weeks), an 8-week cycle requires approximately 3–4 vials of BPC-157 (5 mg each, yielding 10 days of 500 mcg/day per vial) and 3–4 vials of TB-500 (5 mg each). Exact count depends on reconstitution volume, loading dose selection, and whether any waste occurs during reconstitution or drawing.
Is the Wolverine Stack banned in sports?
Yes — both BPC-157 and TB-500 (Thymosin Beta-4 and its fragments) appear on the WADA Prohibited List. They are banned both in-competition and out-of-competition. The 2025 systematic review documented that major professional and collegiate sports organizations — including the NFL, NBA, MLB, NHL, NCAA, UFC, and PGA — also prohibit these compounds, either by name or by classification as peptide hormones. Athletes subject to any level of anti-doping testing should assume the Wolverine Stack is prohibited.
This article is for educational and informational purposes only and does not constitute medical advice. Peptides discussed may be investigational compounds not approved by the FDA for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.
